DROLET STOCK NOTE: LEANLIFE HEALTH TO DISTRIBUTE BOXING LEGEND MIKE TYSON IRON ENERGY DRINK IN NORTH AMERICA - INVESTORINTEL

Drolet Stock Note: LeanLife
Health to Distribute Boxing
Legend Mike Tyson Iron Energy
Drink in North America
Mario Drolet, President of MI3 Communications Financières Inc.
(MI3), released his Stock Notes on LeanLife Health Inc. (CSE:
LLP) for exclusive distribution on InvestorIntel. Highlights
include:

     LeanLife Health’s products are long-term, shelf-stable
     extractions from flax seed, a plentiful plant-based
     source of Omega-3, that give them a significant
     advantage as an essential fortified food ingredient.
     LeanLife Health’s industry-leading and proprietary
     Omega-3 product formulations are of the highest quality
     and contain no cholesterol.
     LLP to distribute for Mike Tyson Iron Energy Drink in
     North America
     The global Omega-3 market reached USD $33 Billion in
     2016 and is expected to reach upwards of USD $57 Billion
     by 2025, according to a report by Grand View Research,
     Inc.
     Surge in Volume in July from $0.03 to $0.08
     LLP traded over 29 million shares since July 1
     Support:    S2; $0.03    S1; $0.045
     Resistance:    R1; $0.06    R2; $0.08

About LeanLife Health

LeanLife Health’s products are long-term shelf-stable
extractions from flax seed, a plentiful plant-based source of
Omega-3, that give them a significant advantage as an
essential fortified food ingredient. Increased Omega-3 intake,
especially with LeanLife’s higher Omega-3 to -6 ratio, has
shown to have significant health improvement impacts.

LeanLife’s mission is to provide a relatively low-cost means
of replacing the less healthy vegetable oil in food,
and transform them into healthier versions.

PLEASE DO YOUR DUE DILIGENCE

Disclaimer: This MI3 Technical Note produced by MI³
Communications Financières is neither an offer to sell, nor
the solicitation of an offer to buy any of the securities

discussed therein. The information contained is prepared by
MI3, emanating from sources deemed to be reliable. MI3
Communications Financières makes no representations or
warranties with respect to the accuracy, correctness or
completeness of such information. MI³ Communications
Financières accepts no liability whatsoever for any loss
arising from the use of the information contained therein.
Please take note that for compliance purposes, all directors,
consultants or employees of MI3 Communications Financières are
prohibited from trading the securities of the company and MI3
Communications Financières is a shareholder and do not intend
to sell any shares during the distribution of this report.

Early cancer detection in the
spotlight in the wake of
actor   Chadwick   Boseman’s
tragic death

New technology offers hope for early
detection and survivability
The recent passing of Black Panther star Chadwick Boseman at
only age 43 from colon cancer has shone the spotlight again on
this deadly disease. Many are asking why we cannot detect and
cure cancer. Surely if we find it early it can be cured?
Cancer is a terrible disease that now kills one in six people
globally. In 2017 cancer killed 9.6 million people. The
statistic alone is staggering but the sad part is, with early
detection many cancers could be treated and cured. The problem

is a lack of awareness that results in a lack of early
testing.

One company is hoping to change that with their next
generation “10 in 1” early stage cancer blood test called
Aristotle®.

That company is StageZero Life Sciences Ltd. (TSX: SZLS).
StageZero is best known for their early stage cancer testing.
In particular their Aristotle® “10 in 1” blood test to detect
any of 10 early stage cancers. Using their diagnostic
expertise, in 2020 StageZero also successfully began doing
COVID-19 testing.

StageZero Life Sciences is able to screen for cancer and test
for COVID-19

Source

Aristotle® 10 in 1 cancer screening

Aristotle® is a panel for simultaneously screening for 10
different cancers from a single sample of blood. Aristotle®
has been built on StageZero’s proprietary mRNA technology
platform, which was validated in more than 10,000 patients for
the development of the first liquid biopsy for colorectal
cancer (ColonSentry®).

Aristotle® is the result of 15 years of development and
StageZero believes its test is more accurate and better than
standard cancer screening tests. It also has the advantage of

screening for ten cancers in one test, compared to
competitors’ single test/single cancer detection. It is little
wonder that StageZero chose the name ‘Aristotle’ after the
Greek philosopher, as it means ‘best‘ in Greek.

StageZero expects to begin commercializing their Aristiotle®
test by the end of this year. Examples of the cancers covered
by the Aristotle test include colo-rectal (bowel), bladder,
prostate, liver, nasopharyngeal, stomach, breast, ovarian,
cervical, and endometrial cancers.

StageZero Life Sciences Aristotle® has very high accuracy
testing for 10 cancers in 1 blood test

Source

Given that Aristotle® is still relatively new, one of the
challenges is increasing awareness both among the medical
community but also among potential patients to inform them
that there is now a new and very effective way to do an early
screening for not one, not two, but TEN cancer tests in one
simple blood test.

Step by step, the word is beginning to get out about
StageZero’s revolutionary 10 in 1 cancer screening test. For
example, an abstract entitled “Aristotle: A Single Blood Test
for Pan Cancer Screening” was selected for online publication
at the annual meeting of the American Society of Clinical
Oncology (“ASCO”).

StageZero has a growing network of partners including those on
the telehealth platform such as with 10,000 mobile
phlebotomists, physician groups, and small and large
businesses such as Mercer. Ironically, COVID-19 has helped
accelerate the number of new partners and awareness for
StageZero’s products.

Applying the technology to COVID-19 testing

In April 2020, in response to the COVID-19 pandemic, StageZero
announced that they will offer both the PCR-based nucleic acid
tests as well as qualitative antibody testing for COVID-19.
Since that time StageZero has initiated COVID-19 testing with
both PCR and antibodies, with initial interest received by the
company represented by approximately US$18m+ in revenue. Other
StageZero achievements include:

     Beckman Coulter received the EUA from the FDA for its
     SARS-CoV-2 IgG Antibody Test.
     Partnered with 5 initial groups.
     City of Alpharetta offered StageZero COVID-19 testing to
     its first responders.
     Partnership with UDo Test connected the Company to a
     network of 50,000 physicians.
     Mercer VIP Program included StageZero COVID-19 testing
     and connected the company to numerous employers who have
     ordered tests. StageZero is now a preferred lab for
     Mercer.

StageZero has been busy raising capital to support the above
recent activities and expansion. In late June StageZero
successfully raised C$4.6m from an equity placement. The funds
will be used for hiring staff, purchasing equipment, test
reagents, and consumable materials (for COVID-19 Tests and
Aristotle®).

Closing remarks

There is little doubt that early screening for cancer can save
lives. Even better is if a patient can be tested for 10
cancers all in 1 simple blood test. It makes routine screening
ten times more worthwhile and it may just help to save your
life, your relative’s life, or a celebrity’s life.

StageZero is steadily gaining awareness and distribution of
their COVID-19 and soon Aristotle® cancer screening test with

plans to commercialize Aristotle® by end 2020. The fact that
they are also currently providing COVID-19 screening is both
boosting revenues and awareness about StageZero. StageZero has
potential for revenues to surge in 2020 and beyond as their
testing and screening tests potentially become more widely
used. The company is cashed up after a June C$4.6m capital
raise.

The current market cap of StageZero is just C$35m. Analyst
price target is C$0.50, which is well above the current stock
price of C$0.09. StageZero Life Sciences is a very exciting
company at a very exciting time in their development. They
have huge potential to help society and at the same time be a
big winner for early investors. Don’t miss this one.

Further learning

     James   Howard-Tripp   on   applying   StageZero’s   cancer
     diagnostics expertise to COVID-19 testing

James    Howard-Tripp    on
applying StageZero’s cancer
diagnostics   expertise  to
COVID-19 testing
InvestorIntel’s Tracy Weslosky talks with James Howard-Tripp,
Chairman and CEO of StageZero Life Sciences Ltd. (TSX: SZLS),
about StageZero’s early detection of cancer diagnostics and
its new testing technology for COVID-19. Tracy observed, “You
have one of the highest volume stock. You recently had a buy
recommendation from Clarus Securities. What do you attribute

all this recent attention to?” she asked.

“Fifteen years of work,” James replied.

“We are a cancer diagnostic company. So, when you deal with
cancer everything needs to be absolutely precise,” James
added. “When you move into another line, which is testing for
COVID-19, you have to bring the exact same rigor to it.
Everything that we do is to ensure that it is as precise as
possible.” StageZero’s Aristotle testing platform can identify
ten different types of cancer from a single blood test. “We
believe that it will be in the market by year end. We are now
completing the last of the validation,” James said.

To watch the complete interview, click here

Disclaimer: StageZero Life Sciences Ltd. is an advertorial
member of InvestorIntel Corp.

XPhyto   Therapeutics Hugh
Rogers talks about rapid-
results virus testing
InvestorIntel’s Peter Clausi talks with Hugh Rogers, CEO and
Director of XPhyto Therapeutics Corp. (CSE: XPHY | OTCQB:
XPHYF) about XPhyto’s COVID-19 testing program. “Our goal was
to develop a test that could produce results in less than 15
minutes, and we are now, in lab, generating results in less
than 5 minutes,” Hugh said. “We have an enhanced probe system
that does not require equipment. Our detection is capable of
detecting the virus within the full range of infection – that
is, pre-symptomatic, asymptomatic as well as on the tail end

of an infection.”

Hugh went on to say, “We have drug development platforms and a
number of programs. We are more diversified than just a
testing company.” He added that their “lead program on the
transdermal side is a Parkinson’s generic called Rotigotine, a
slow release patch, and our lead program on the oral
dissolvable side is CBD based for epilepsy. It is many times
more efficient than an oil-based system. It is faster. It is
more predictable.”

To watch the complete interview, click here

Disclaimer: XPhyto Therapeutics Corp. is an advertorial member
of InvestorIntel Corp.

Sixth Wave Innovations leads
virus   detection    through
breath testing

Using nanotechnology to quickly identify
pathogens
Imagine if taking a coronavirus test was as simple as an
alcohol breathalyzer, or a pregnancy test, and the results
just as fast. One company has developed a test that uses
molecular imprinted polymers with the possibility of detecting
almost any pathogen, and is now using their technology to
develop a way to detect for COVID-19 as easily as using a
saliva test or a swab test.

Sixth Wave Innovations (CSE: SIXW | OTCQB: ATURF | FSE: AHUH)
is a development stage nanotechnology company with patented
technologies that focus on the extraction and detection of
target substances at the molecular level using highly
specialized ‘molecular imprinted polymers’ (MIPs). The target
substances can be anything, such as pathogens (viruses &
bacteria), gold, or anything made of molecules (that’s every
substance).

Sixth Wave has technology to make a ‘polymer imprint’ for
molecules including viruses. Sixth Wave is working to develop
a molecular imprint for the coronavirus so they can capture
the virus in their polymer and then apply various techniques
to detect the virus such as colormetrics or electronics.

The company is working toward incorporating the technology
into a mask so you could wear a mask that both protects and
detects for COVID-19. Another concept is to have the MIP
inside a coated barcode strip which you would then scan with
your smartphone to see if you have been infected or not. (See:
Sixth Wave working on a virus breath test.)

President, CEO and Founder Dr. Jonathan Gluckman explained
that a “virus has a size and shape and we create an imprint in
our polymer for that exact virus. Then we will detect that
directly based on our chemistry.” He continued that Sixth Wave
is “working to integrate this into masks and breathalyzers and
then we can just utilize the breath, as we all know that’s the
main transmission method. If you think about putting a mask
on, not only will that mask provide protection, it can also,
right there, be the test for COVID-19.”

Highlighting the advantages of Sixth Wave’s COVID-19 test over
other tests, Dr. Gluckman also said that the test will be
cheaper, faster, less invasive, and easy to use.

Dr. Gluckman says that Sixth Wave’s COVID-19 detection
technology is currently under development, but the Company has

successfully launched and commercialized other products with
similar properties. The coronavirus tests are planned to be
ready for an early 2021 rollout. The company has received a
grant from the Canadian government to work with York
University and the CTRI to use its virus detection technology
to detect COVID-19 virus in wastewater supplies and in air
handling systems.

Sixth Wave Innovations can detect and extract anything at the
molecular level – Target markets include COVID-19 testing,
gold extraction, and cannabis purification

Source

Sixth Wave Innovations technology can be used for other
applications

Gold extraction

IXOS ® is a line of extraction polymers for the gold mining
industry 100% developed and owned by Sixth Wave and
patented/patent pending in 40+ countries worldwide. CEO
Gluckman says the technology can save gold mining companies
about US$100/oz on their processing costs based on pilot scale
test results for multiple mines.

Sixth Wave Innovations IXOS ® can save gold miners up to

US$100/oz in gold processing costs

Source: Corporate presentation

Cannabis Purification

Sixth Wave is in the process of commercializing its AffinityTM
cannabinoid purification system. The Affinity™ Technology for
the medical and recreational cannabis industry is 100%
developed and owned by Sixth Wave with a patent pending.

Affinity T M products are now rolling out and starting to
generate revenue for Sixth Wave, including an initial 300
Affinity units.

Other applications

Sixth Wave’s Molecular Imprinted Polymers (MIPs) have also
been applied in industries including security (SAFE-T
explosives detective wipes), mining (gold & silver extraction,
also removal of mercury), and other pathogen detection. The
potential list of applications is enormous.

Sixth Wave Innovations planned revenue streams

Source: Corporate presentation

Closing remarks

History has repeatedly shown how mankind makes incredible
innovative technology during incredible times. Here we are
facing one of this century’s greatest pandemics and scientists
globally are racing to develop better diagnostic tests,
treatments and vaccines.

In the case of Sixth Wave Innovations it is fast-tracking the
development of an innovative technology to detect and extract
polymer molecules. They are now focused on adapting their
technology to make a polymer imprint of the coronavirus that
can, if successful, make COVID-19 detection as simple and fast
as a breath test, whether on a test strip or even on a dual-
purpose face mask. Imagine wearing a face mask that can also
detect COVID-19. Sixth Wave’s COVID-19 detection technology
targeted for early 2021, and if successful it will be a
massive win-win for the public and also for Sixth Wave
Innovations.

Meanwhile, Sixth Wave will be advancing their near term

revenues from AffinityTM, and later hopefully from IXOS®. The
current market cap of Sixth Wave Innovations is only C$21m
thereby presenting a tremendous early stage speculative
opportunity for investors.

XPhyto Therapeutics moving
forward    from  successful
prototype testing of saliva
virus test

Non-invasive test can detect viral RNA in
asymptomatic patients
XPhyto Therapeutics Corp. (CSE: XPHY | OTCQB: XPHYF | FSE:
4XT) (“XPhyto”) is a next generation bioscience company with a
rapid pathogen screening systems division, including a new,
non-invasive coronavirus saliva test. This is an important
addition to rest of their businesses which includes advanced
drug delivery systems (Vektor Pharma) and cannabis investments
(Vektor Pharma & Bunker).

XPhyto’s core business is drug delivery, diagnostic, and
cannabis investment opportunities focused on European markets,
especially Germany.

Source: Company presentation

XPhyto’s rapid pathogen screening systems

XPhyto is focused on developing rapid, low-cost, screening
tools for pandemic threats. The company, along with their
diagnostic partner 3a-Diagnostics GmbH (“3a”), has recently
become better known for their COVID-19 RNA testing. The XPhyto
team is developing a rapid, disposable, point-of-screening
test to detect COVID-19 viral RNA from patient saliva as well
as more traditional nasal and throat swabs. On July 6, 2020,
XPhyto announced successful validation of its working test
prototype. The test, as observed and reported by clinicians
and scientists in peer reviewed publications, demonstrated a
detection limit capable of identifying viral RNA in the saliva
of symptomatic, pre-symptomatic, and asymptomatic patients.
Subject to fast track certification by the German government,
XPhyto and 3a are targeting Q1 2021 for European regulatory
approval and commercial sales.

Being able to detect coronavirus early in patients with no
symptoms has been identified as a key factor in halting the
spread. A saliva-based test is another huge advantage due to
the ease of testing compared to the current nasal swab
testing, which can range from uncomfortable to painful.

The technology behind the new test will also be suitable for
other types of coronaviruses in the long term. XPhyto and 3a
are also in the process of developing rapid screening tests
for other pandemic threats, including H1N1 (swine flu) and
H5N1 (avian flu), with a specific focus on identifying early
pre-symptomatic stages of infection.

XPhyto’s advanced drug delivery systems

XPhyto owns Vektor Pharma, a German narcotics manufacturer,
importer and researcher. Vektor Pharma is a decade-long leader
in design, testing and manufacture of thin film drug delivery
systems including transdermal patches, oral dissolvable film
(ODF), sub-lingual (oral) strips for the clinical management
of pain, and an ODF biosensor delivery platform. Vektor Pharma
currently holds numerous narcotics import and manufacturing
licenses, including cannabis imports and authorizations
related to conventional and cannabis-related prescription
medications.

XPhyto’s cannabis investments

XPhyto also 100% owns Bunker. Bunker has a unique German
cannabis cultivation and extraction license for scientific
purposes. Subject to BfArM (the Federal Institute for Drugs
and Medical Devices) security requirements, the license
authorizes cultivation and extract of 70 different strains of
Cannabis Sativa and Cannabis Indica for scientific purposes.

XPhyto also has an exclusive LOI and standstill agreement for
cooperation in the field of development, production, and
distribution of new cannabis-infused beverages and products
with the famous German brewery Oettinger. Oettinger beer is
not only one of the best selling beers in Germany, it is also
internationally recognized as one of the largest brewery
groups in the world.

XPhyto Therapeutics Corp. is well-placed in key emerging
industries

Source: Company presentation

Closing remarks

XPhyto is an innovator in the increasingly important fields of
virus detection and drug delivery systems, including the vital
area of mass rapid pathogen screening testing. Added to that,
it has some exciting cannabis related investments,
particularly with Bunker in Germany. XPhyto also has R&D
collaborations with the technical University of Munich and the
University of Alberta.

For investors, XPhyto Therapeutics Corp. trades on a market
cap of C$165m and the stock is up an impressive 132% in the
past year. While a non-invasive COVID-19 saliva test that can
detect the virus in both symptomatic and asymptomatic patients
would have immediate and obvious benefits, it could also have
long-term applicability to other pathogens going forward.
Added to XPhyto’s carefully curated suite of other diagnostic,
drug delivery and cannabis licenses, it makes it a company to
watch.

MiCOVID      Cam     thermal
temperature screening helps
schools and businesses reopen
safely

Direct Communication Solutions leads the
way in smart, unmanned screening tech
COVID-19 continues to spread globally, now at a staggering
22,306,538 confirmed cases and 784,353 deaths. Companies
developing technologies to quickly and accurately screen for
possible COVID-19 cases in the community are seeing their
stock prices surge. There is one small company that has
developed a new AI thermal detector with cutting edge facial
recognition which is currently under the radar of investors.

That company is Direct Communication Solutions Inc. (CSE: DCSI
| OTCQB: DCSX) (“DCS”), an Internet of Things (IoTs) solutions
company. IoTs solutions provide better ways for businesses to
collect and assess business-critical data from all types of
assets and devices using their hardware, software applications
and scalable cloud services.

In late July 2020, DCS announced their latest product, a new
AI thermal detector with cutting edge facial recognition and
body temperature detection, known as MiCOVID Cam. DCS say that
by “utilizing the latest AI chipset technology, MiCOVID Cam
offers immediate body temperature detection, the longest
sensor range, and the highest level of accuracy available in
the market today.” The MiCOVID Cam is fully integrated into

the DCS Web Services offering. DCS has also developed a 7 in 1
sensor which is significantly cheaper and offers seven sensors
packaged together compared to competitors just one sensor.

Direct Communication Solutions new MiCOVID cam is designed to
automatically screen for COVID-19 in businesses and schools

Source

A unique feature to DCS’s MiCOVID Cam is it offers employers a
web-based solution without the need for operators by using its
advanced AI. This makes it a cost-effective solution for
screening the temperatures of visitors, employees or students.
MiCOVID Cam can even automatically detect if employees or
customers are wearing a mask or not. Employers can save the
costs of manual screening by automating the whole process. In
some cases the US CARES Act has paid for screening devices,
recognizing the urgent need for better screening.

Fast mass screening has been a challenge. The MiCOVID Cam
solution is capable of automatically screening up to 2,400
persons per hour, making it ideal for large businesses,
organizations and schools.

The MiCOVID Cam in use at a Poland School District
automatically screening students, staff, and teachers

Source: You can watch the video here.

David Scowby, COO of DCS explains that the “MiCovid Cam is
another milestone achievement for DCS and fits into our
strategy of providing our IoT technologies and Web Services to
our partners developing next generation software applications…
It is a unique time where our economy is needing the support
to reopen, and offering MiCovid Cam is a way for businesses to
reopen with advanced safety solutions.”

These are certainly unique times. COVID-19 continues to spread
through the community and screening measures such as the DCS
MiCOVID Cam is a much needed smart product to help identify
and minimize the spread of COVID-19, or other infectious
diseases with a thermal imprint. The automatic screening
without the need of staff is a significant and natural
advantage for DCS, as they offer a suite of web-connected IoTs
solutions for their customers.

DCS’s technologies is already established in California and

has a growing number of partners including Sprint, Cellcom,
Bluegrass Cellular, Bell, CCA, Inland Cellular, US Cellular,
SkyEye GPS, Verizon, and Telus. Strategic partners include
Queclink, Cal/Amp. Telit, ATrack, and GoldenM.

Closing remarks

I think DCS’s MiCOVID Cam is a significant and timely addition
to the company’s sensor technologies and can be an important
tool in the fight to slow the spread of COVID-19, so a win-win
for all. Added to MiCOVID Cam, DCS has three other key IoTS
products – MiFleet (GPS tracking), MiSensors (remote
monitoring system), and Brewsee (a beer life cycle monitor &
control system). All of this is part of what is a rapidly
growing IoTs global market forecast to reach US$1.1 trillion
by 2023 and with a forecast 21.5 billion connected devices
worldwide by 2025.

Direct Communication Solutions Inc. is currently trading on a
market cap of just C$14.7m despite last year having C$16m in
revenue, essentially at a valuation of below 1x revenue, which
is generally considered very cheap. This is before factoring
in any potential future revenues from their new MiCOVID Cam
solution. Investors may not want to wait too long on this one
as cutting-edge technologies tend to move quickly once
discovered by industry and investors.